(Press-News.org) A new Ebola virus study resulting from a widespread scientific collaboration has shown promising preliminary results, preventing disease in infected nonhuman primates using monoclonal antibodies.
In this week's online edition of the Proceedings of the National Academy of Sciences (PNAS), the research team describes a proof-of-concept for using a "cocktail" of monoclonal antibodies, or mAbs, to prevent lethal disease in rhesus macaques. When administered one hour after infection, all animals survived. Two-thirds of the animals were protected even when the treatment, known as MB-003, was administered 48 hours after infection.
Ebola virus, which causes hemorrhagic fever with human case fatality rates as high as 90 percent, has been responsible for numerous deaths in central Africa over the past several months. In addition to being a global health concern, the virus also is considered a potential biological threat agent. Currently there are no available vaccines or treatments approved for use in humans.
The work is the culmination of more than a decade of effort between government and industry partners. According to lead investigator Gene Olinger, Ph.D., a virologist at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), this consortium of investigators has taken very distinct technologies and combined them to develop a cutting-edge medical countermeasure against a lethal viral disease.
"It is rare that an antiviral compound prevents Ebola virus infection with limited to no morbidity in treated animals at any point of treatment following infection by this lethal virus," said Olinger. "Until recently, attempts to utilize antibodies to provide protection against Ebola virus have been met with failure. The level of protection against disease that we saw with MB-003 was impressive."
In addition, the production method used in this study offers the potential to make an economical and effective medical countermeasure, according to the authors. Initially developed as a monoclonal antibody cocktail in the mouse model, MB-003 was successfully humanized and then produced in the tobacco plant-based production system.
"We were pleased to see how well the humanized mAbs of MB-003 performed," said Larry Zeitlin, Ph.D., president of Mapp Biopharmaceutical and senior author on the study. "We also were pleasantly surprised by the superiority of the plant-derived mAbs compared to the same mAbs produced in traditional mammalian cell culture."
Further improvement in antibody efficacy was developed at Kentucky BioProcessing (KBP). Using a fully automated production system that operates in accordance with good manufacturing practices (GMP), antibody is produced in a tobacco plant system. This new development process significantly decreases the amount of time required for production, increases the quantity of antibody produced, and slashes the cost of manufacturing, according to Barry Bratcher, chief operating officer of KBP and co-author on the PNAS study.
"Our GMP facility can generate a new antibody lot in two weeks to rapidly address new threats and new outbreaks," said Bratcher.
Olinger said efforts are underway to advance MB-003 to clinical safety testing as his team at USAMRIID continues to determine the true therapeutic capability of the cocktail.
###
Multiple agencies contributed funding for this and related studies, including the National Institutes of Health, the Defense Advanced Research Projects Agency, the Transformational Medical Technologies Initiative, and the Defense Threat Reduction Agency.
USAMRIID's mission is to protect the warfighter from biological threats and to be prepared to investigate disease outbreaks or threats to public health. Research conducted at USAMRIID leads to medical solutions—vaccines, drugs, diagnostics, and information—that benefit both military personnel and civilians. The Institute plays a key role as the lead military medical research laboratory for the Defense Threat Reduction Agency's Joint Science and Technology Office for Chemical and Biological Defense. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command.
Ebola antibody treatment, produced in plants, protects monkeys from lethal disease
2012-10-16
ELSE PRESS RELEASES FROM THIS DATE:
University of Maryland School of Medicine scientists develop stem cell model for hereditary disease
2012-10-16
A new method of using adult stem cells as a model for the hereditary condition Gaucher disease could help accelerate the discovery of new, more effective therapies for this and other conditions such as Parkinson's, according to new research from the University of Maryland School of Medicine.
Scientists at the University of Maryland School of Medicine reprogrammed stem cells to develop into cells that are genetically similar to and react to drugs in a similar way as cells from patients with Gaucher disease. The stem cells will allow the scientists to test potential new ...
UW-Madison archaeologists to mount new expedition to Troy
2012-10-16
MADISON -- Troy, the palatial city of prehistory, sacked by the Greeks through trickery and a fabled wooden horse, will be excavated anew beginning in 2013 by a cross-disciplinary team of archaeologists and other scientists, it was announced today (Monday, Oct. 15).
The new expedition will be led by University of Wisconsin-Madison classics Professor William Aylward, an archaeologist with long experience digging in the ruins of classical antiquity, including Troy itself. The new international project at Troy, to be conducted under the auspices of and in cooperation with ...
Penn researchers find new way to prevent cracking in nanoparticle films
2012-10-16
PHILADELPHIA — Making uniform coatings is a common engineering challenge, and, when working at the nanoscale, even the tiniest cracks or defects can be a big problem. New research from University of Pennsylvania engineers has shown a new way of avoiding such cracks when depositing thin films of nanoparticles.
The research was led by graduate student Jacob Prosser and assistant professor Daeyeon Lee, both of the Department of Chemical and Biomolecular Engineering in Penn's School of Engineering and Applied Science. Graduate student Teresa Brugarolas and undergraduate ...
Strengthening a billion-dollar gene in soybeans
2012-10-16
Soybean cyst nematode (SCN) does hundreds of millions of dollars' worth of damage each year. Matt Hudson and Brian Diers, crop sciences researchers at the University of Illinois and Andrew Bent at the University of Wisconsin, think they may have found a way to strengthen plant resistance. The research has just been published in Science Express.
Diers and Hudson, with researchers at Wisconsin and the University of Nebraska, have been studying an area on chromosome 18 called Rhg1 (Resistance to H. glycines) that is known to be the location of the main source of SCN resistance. ...
Social contact can ease pain related to nerve damage, animal study suggests
2012-10-16
COLUMBUS, Ohio – Companionship has the potential to reduce pain linked to nerve damage, according to a new study.
Mice that were paired with a cage-mate showed lower pain responses and fewer signs of inflammation in their nervous system after undergoing surgery that affected their nerves than did isolated mice, suggesting that the social contact had both behavioral and physiological influences.
The social contact lowered the pain response and signs of inflammation even in animals that had experienced stress prior to the nerve injury.
These mice experienced a specific ...
23andMe compares family history and genetic tests for predicting complex disease risk
2012-10-16
MOUNTAIN VIEW, CA – October 15, 2012 – In a new theoretical study, 23andMe, the leading personal genetics company, developed a mathematical model which shows that family history and genetic tests offer different strengths. The study results suggest that both family history and genetics are best used in combination to improve disease risk prediction. The full results of the study have now been published online in the journal PLOS Genetics.
Family history is most useful in assessing risks for highly common, heritable conditions such as coronary artery disease. However, ...
One foot from the grave!
2012-10-16
Archaeologists from the University of Leicester who uncovered a grave thought to contain the skeleton of King Richard III have revealed that the remains came within inches of being destroyed by Victorian builders.
The University of Leicester led the search for the Anointed King who died at the battle of Bosworth in association with Leicester City Council and the Richard III Society. The University team dug three trenches under a Leicester car park before their discovery was made.
Now site director Mathew Morris has disclosed that the remains were found just inches below ...
'Biggest Loser' study finds modest diet and exercise can sustain weight loss
2012-10-16
Exercise and healthy eating reduce body fat and preserve muscle in adults better than diet alone, according to a study funded and conducted by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health. The study was recently published online in Obesity and will be in a future print edition.
NIDDK senior investigator Kevin Hall, Ph.D., analyzed the individual effects of daily strenuous exercise and a restricted diet by examining data from 11 participants from the reality television program "The Biggest Loser." ...
Prebiotic may help patients with intestinal failure grow new and better gut
2012-10-16
URBANA – Adding the right prebiotic to the diets of pediatric patients with intestinal failure could replace intravenous feeding, says a new University of Illinois study.
"When we fed the carbohydrate fructooligosacharide (FOS) as a prebiotic, the gut grew and increased in function," said Kelly A. Tappenden, a U of I professor of nutrition and gastrointestinal physiology. "The study showed that using the correct pre- and probiotic in combination could enhance these results even more."
When FOS enters the intestines, bacteria convert it into butyrate, a short-chain fatty ...
Wake Forest Baptist researcher pieces together AML prognosis puzzle
2012-10-16
WINSTON-SALEM, N.C. – Oct. 15, 2012 – When patients suffering from Acute Myeloid Leukemia (AML) express high levels of the gene, MN1, an already aggressive leukemia is accelerated and shortens survival time. While that's a known fact, the mechanisms involved aren't well understood which is why a Wake Forest Baptist Medical Center researcher decided to take a closer look.
Timothy S. Pardee, M.D., Ph.D., an assistant professor of hematology and oncology at Wake Forest Baptist, said that previous studies of AML have shown that when patients express high levels of the MN1 ...